D-1262-2020 Class III Terminated
FDA drug recall D-1262-2020 was initiated by The Harvard Drug Group on Apr 24, 2020 and is designated Class III. Reason for recall: Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing. The recall status is terminated (terminated Aug 19, 2022). Affected quantity: 678 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- May 20, 2020
- Initiation Date
- Apr 24, 2020
- Termination Date
- Aug 19, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 678 cartons
Product description
Memantine Hydrochloride Extended-Release Capsules, 28 mg, 100 capsules per unit dose cartons, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.)-454 775, India; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 47152 USA. NDC: 0904-6735-61
Reason for recall
Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing.
Distribution pattern
AL, FL, IA, NY, OH, TX
Code information
Lot #: M02199D, M02246D, Exp 5/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1262-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026